Published in Cancer Discov on August 05, 2014
Prognostic Biomarkers in Patients With Urothelial Carcinoma | NCT04872036
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol (2015) 1.90
Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS One (2015) 1.51
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine (2016) 1.50
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res (2015) 1.09
Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A (2015) 1.06
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. Oncologist (2015) 1.04
PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets. Cancer Res (2015) 0.95
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. Urol Oncol (2015) 0.91
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res (2015) 0.88
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet (2016) 0.86
The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. Nat Rev Urol (2016) 0.81
Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol (2016) 0.81
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol (2016) 0.81
Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer (2016) 0.81
Molecular biology of bladder cancer. Hematol Oncol Clin North Am (2015) 0.80
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder. Oncoimmunology (2016) 0.79
Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clin Genitourin Cancer (2015) 0.79
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clin Genitourin Cancer (2015) 0.79
Urothelial carcinoma management in elderly or unfit patients. EJC Suppl (2016) 0.78
Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer. Bladder Cancer (2016) 0.78
Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines. Nat Rev Urol (2016) 0.78
Circulating Biomarkers in Bladder Cancer. Bladder Cancer (2016) 0.77
DNA Repair Pathway Alterations in Bladder Cancer. Cancers (Basel) (2017) 0.77
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Sci Rep (2016) 0.77
Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer. Transl Androl Urol (2015) 0.77
Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clin Genitourin Cancer (2016) 0.76
An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. Biomolecules (2016) 0.76
Precision medicine for advanced prostate cancer. Curr Opin Urol (2016) 0.76
Novel molecular targets for urothelial carcinoma. Expert Opin Ther Targets (2015) 0.76
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clin Cancer Res (2017) 0.76
The NF1 gene in tumor syndromes and melanoma. Lab Invest (2017) 0.75
Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study. Bladder Cancer (2017) 0.75
Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiol (2016) 0.75
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clin Genitourin Cancer (2015) 0.75
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer (2016) 0.75
The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol (2016) 0.75
Testing the metal of ERCC2 in predicting the response to platinum-based therapy. Cancer Discov (2014) 0.75
Bladder cancer: A step closer to individualized treatment for bladder cancer. Nat Rev Urol (2015) 0.75
New discoveries in the molecular landscape of bladder cancer. F1000Res (2016) 0.75
Systemic therapy for bladder cancer finally comes into a new age. Future Oncol (2016) 0.75
Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer (2016) 0.75
Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing. Transl Androl Urol (2016) 0.75
Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer. Urol Clin North Am (2015) 0.75
Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet (2016) 0.75
Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers. Oncoscience (2015) 0.75
ARF confers a context-dependent response to chemotherapy in muscle invasive bladder cancer. Cancer Res (2017) 0.75
SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016). Clin Transl Oncol (2016) 0.75
Dose dense MVAC prior to radical cystectomy: a real-world experience. World J Urol (2017) 0.75
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
DNA damage, aging, and cancer. N Engl J Med (2009) 7.56
Transcription-coupled DNA repair: two decades of progress and surprises. Nat Rev Mol Cell Biol (2008) 7.00
Genome sequencing identifies a basis for everolimus sensitivity. Science (2012) 6.71
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol (2005) 6.38
Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol (2005) 4.57
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol (2009) 4.19
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics (2011) 2.90
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res (2002) 2.09
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol (2007) 2.01
Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol (2013) 1.92
A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Hum Mutat (1999) 1.87
A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol (1996) 1.69
TFIIH: when transcription met DNA repair. Nat Rev Mol Cell Biol (2012) 1.63
Analysis of the essential and excision repair functions of the RAD3 gene of Saccharomyces cerevisiae by mutagenesis. Mol Cell Biol (1986) 1.56
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer (2009) 1.46
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J (2009) 1.28
Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol (2009) 1.17
ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol (2008) 1.15
Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol (2010) 1.14
A novel high-throughput (HTP) cloning strategy for site-directed designed chimeragenesis and mutation using the Gateway cloning system. Nucleic Acids Res (2005) 1.09
Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int (2013) 1.03
Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res (2002) 1.02
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. Cancer Chemother Pharmacol (2012) 0.86
XPD mutations in trichothiodystrophy hamper collagen VI expression and reveal a role of TFIIH in transcription derepression. Hum Mol Genet (2012) 0.83
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol (2016) 3.48
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov (2014) 1.21
A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res (2015) 1.09
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunol Res (2015) 1.08
Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov (2016) 0.83
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res (2015) 0.82
Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer (2016) 0.81
Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. J Urol (2015) 0.80
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer (2015) 0.78
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clin Cancer Res (2017) 0.76
Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. Clin Cancer Res (2016) 0.75
Osteochondroma in long-term survivors of high-risk neuroblastoma. Cancer (2015) 0.75
Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy. JAMA Oncol (2017) 0.75
Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer (2017) 0.75
Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States: A Nationwide Survey Analysis. JAMA Oncol (2016) 0.75